Floatz logo

SHP-141

Cutaneous T-Cell Lymphoma (CTCL)

TetraLogic PharmaceuticalsPhase 2Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

62 Active assets in the Cutaneous T-Cell Lymphoma (CTCL) cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Cyclophosphamide
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Bexarotene
Case Comprehensive Cancer Center
Phase 4BBB
DEXAMETHASONE
National Cancer Institute (NCI)
Phase 2BBB
Inno-206
Falo, Louis, MD
Phase 4BBB

View all 50 →

Same molecule, other indications

SHP-141 is also rated in:

primary cutaneous T-cell non-Hodgkin lymphomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →